Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities
Lateral flow assays (LFAs) are the mainstay of rapid point-of-care diagnostics, with the potential to enable early case management and transform the epidemiology of infectious disease. However, most LFAs only detect single biomarkers. Recognizing the complex nature of human disease, overlapping symp...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-09-01
|
Series: | Diagnostics |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4418/7/3/51 |
id |
doaj-b1032ecf35b74875afbb98c89b9761bf |
---|---|
record_format |
Article |
spelling |
doaj-b1032ecf35b74875afbb98c89b9761bf2020-11-24T21:54:11ZengMDPI AGDiagnostics2075-44182017-09-01735110.3390/diagnostics7030051diagnostics7030051Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and OpportunitiesKhayriyyah Mohd Hanafiah0Norsyahida Arifin1Yazmin Bustami2Rahmah Noordin3Mary Garcia4David Anderson5School of Biological Sciences, Universiti Sains Malaysia, Penang 11800, MalaysiaInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang 11800, MalaysiaSchool of Biological Sciences, Universiti Sains Malaysia, Penang 11800, MalaysiaInstitute for Research in Molecular Medicine, Universiti Sains Malaysia, Penang 11800, MalaysiaLife Sciences, Macfarlane Burnet Institute, Melbourne 3004, AustraliaLife Sciences, Macfarlane Burnet Institute, Melbourne 3004, AustraliaLateral flow assays (LFAs) are the mainstay of rapid point-of-care diagnostics, with the potential to enable early case management and transform the epidemiology of infectious disease. However, most LFAs only detect single biomarkers. Recognizing the complex nature of human disease, overlapping symptoms and states of co-infections, there is increasing demand for multiplexed systems that can detect multiple biomarkers simultaneously. Due to innate limitations in the design of traditional membrane-based LFAs, multiplexing is arguably limited to a small number of biomarkers. Here, we summarize the need for multiplexed LFA, key technical and operational challenges for multiplexing, inherent in the design and production of multiplexed LFAs, as well as emerging enabling technologies that may be able to address these challenges. We further identify important areas for research in efforts towards developing multiplexed LFAs for more impactful diagnosis of infectious diseases.https://www.mdpi.com/2075-4418/7/3/51lateral flow assaypoint-of-caremultiplexdiagnostic testinfectious diseaseresource-limited settings |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Khayriyyah Mohd Hanafiah Norsyahida Arifin Yazmin Bustami Rahmah Noordin Mary Garcia David Anderson |
spellingShingle |
Khayriyyah Mohd Hanafiah Norsyahida Arifin Yazmin Bustami Rahmah Noordin Mary Garcia David Anderson Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities Diagnostics lateral flow assay point-of-care multiplex diagnostic test infectious disease resource-limited settings |
author_facet |
Khayriyyah Mohd Hanafiah Norsyahida Arifin Yazmin Bustami Rahmah Noordin Mary Garcia David Anderson |
author_sort |
Khayriyyah Mohd Hanafiah |
title |
Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities |
title_short |
Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities |
title_full |
Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities |
title_fullStr |
Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities |
title_full_unstemmed |
Development of Multiplexed Infectious Disease Lateral Flow Assays: Challenges and Opportunities |
title_sort |
development of multiplexed infectious disease lateral flow assays: challenges and opportunities |
publisher |
MDPI AG |
series |
Diagnostics |
issn |
2075-4418 |
publishDate |
2017-09-01 |
description |
Lateral flow assays (LFAs) are the mainstay of rapid point-of-care diagnostics, with the potential to enable early case management and transform the epidemiology of infectious disease. However, most LFAs only detect single biomarkers. Recognizing the complex nature of human disease, overlapping symptoms and states of co-infections, there is increasing demand for multiplexed systems that can detect multiple biomarkers simultaneously. Due to innate limitations in the design of traditional membrane-based LFAs, multiplexing is arguably limited to a small number of biomarkers. Here, we summarize the need for multiplexed LFA, key technical and operational challenges for multiplexing, inherent in the design and production of multiplexed LFAs, as well as emerging enabling technologies that may be able to address these challenges. We further identify important areas for research in efforts towards developing multiplexed LFAs for more impactful diagnosis of infectious diseases. |
topic |
lateral flow assay point-of-care multiplex diagnostic test infectious disease resource-limited settings |
url |
https://www.mdpi.com/2075-4418/7/3/51 |
work_keys_str_mv |
AT khayriyyahmohdhanafiah developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities AT norsyahidaarifin developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities AT yazminbustami developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities AT rahmahnoordin developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities AT marygarcia developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities AT davidanderson developmentofmultiplexedinfectiousdiseaselateralflowassayschallengesandopportunities |
_version_ |
1725868302414118912 |